Inovio Pharmaceuticals Inc (INO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.45-10.49%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · INO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 86.5% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 66 industry peers
INO — debt issuance
Dated 2026-07-31
Entry into a Material Definitive Agreement. On July 29, 2026, Inovio Pharmaceuticals, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Piper Sandler & Co., as underwriter (the “ Underwriter ”), relating to the issuance and sale by the Company in a public offering of (i) 21,052,632 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), and (ii) accompanying warrants (the “ Warrants ”) to purch…
Why it matters: Cash burn above the estimate could shorten the runway. That matters while the company prepares for a possible launch.
Worry ifQ3 2026 operating net cash burn is reported above $18 million.
Less concerning ifQ3 2026 operating net cash burn is $18 million or less, as estimated.
Why it matters: INOVIO said its cash could last into late Q1 2027, through a possible launch. Delays or higher cash use could narrow that window.
Watch forAfter an FDA approval, INOVIO reports a launch plan and keeps its cash runway at least through late Q1 2027.
Also watch forINOVIO reports cash runway ending before late Q1 2027, or says launch plans need more funding or a delay.
Why it matters: The FDA has not yet given feedback on the trial design. Clear feedback could help set the path after approval.
Watch forFDA gives feedback. INOVIO reports an agreed trial design to confirm results, with clear next steps.
Also watch forFDA asks for a major trial redesign, or no feedback is reported in the next company update.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$315 on $10,000 · ±3.1% | How much price usually moves either way. |
| Bad day | $720 loss on $10,000 · 7.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,683 loss on $10,000 · 76.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.